- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05866848
Effects of Caffeine on Cerebral Blood Flow
Effects of Caffeine on Cerebral Blood Flow in Clinically Healthy Young People
The goal of this clinical trial is to evaluate in clinically healthy young people if:
- after caffeine ingestion, there are variations in blood velocity of the middle cerebral arteries (VMCA),
- this variation is dependent on the administered dose.
Transcranial Doppler ultrasonography was used to record blood VMCA in three groups of 15 clinically healthy young adults each - no caffeine, low caffeine (45 mg) and high caffeine group (120 mg). Transcranial Doppler ultrasonography provided simultaneous bilateral VMCA measurements while subjects performed functional tests (hyperventilation and hypoventilation orders) and three cognitive activities (Test 1, short-term remembering, Test 2, solving a vocabulary problem, and Test 3, solving a math problem) each in 31-second tests with 1-minute rest between them. Participants were assessed before and 30 minutes after caffeine ingestion.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Were used in the study, Capsules dosed with 45mg and 120 mg of anhydrous caffeine and flour capsules as a placebo. In the preparation of the capsules, a semi-automatic capsulator No. 0 (Capsunorm® by Tecnyfarma®) were used, colorless hard gelatin capsules No. 0 by Acopharma® and anhydrous caffeine (Biochem®, C.A.S. 58-08-2).
Viasys Sonara transcranial Doppler unit and a 2 MHz probe were used to sample the middle cerebral artery at depths of 60 millimeters, using emission doppler pulsed performing spectral analysis in real time. Two probes (bilaterally) of 2MHz were placed at a depth between 55 and 60 mm, thus making it possible to analyse both middle cerebral arteries simultaneously.
Each participant was asked not to ingest caffeine and exercise vigorously for at least 12 hours before the assessment. In the case of smokers, they were also asked not to smoke for at least 2 hours before the evaluation. The laboratory had medium luminosity, silent and controlled temperature (23º/24ºC). To avoid inter-observer errors, all examinations were performed by the same investigator who was not aware of what dose was/had been administered to the participant.
Subjects were tested while seated in a reclining chair located in a dimly lit, sound-attenuated room and performed the activities with their eyes closed.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Coimbra, Portugal, 3046-854
- Coimbra Health School
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- clinically healthy young people
Exclusion Criteria:
- Individuals with hypertension, high cholesterol, diabetes, arrhythmias, carotid sinus syndrome, severe carotid stenosis and who were in an unstable clinical situation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: No caffeine
The control group took flour capsules.
|
Flour capsules as a placebo.
|
Experimental: Low caffeine
Group with relatively small amount of caffeine (45 mg) administered.
|
Capsules dosed with 45mg of anhydrous caffeine.
|
Experimental: High caffeine
Group with greater amount of caffeine (120 mg) administered.
|
Capsules dosed with 120mg of anhydrous caffeine.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in Mean Velocity (Basal)
Time Frame: 30 minutes
|
Changes in Mean Velocity, measure in m/s from baseline to 30 minutes after caffeine ingestion.
|
30 minutes
|
Changes in Mean Velocity (Hypoventilation)
Time Frame: 30 minutes
|
By performing Hypoventilation, changes in Mean Velocity, measure in m/s from baseline to 30 minutes after caffeine ingestion.
|
30 minutes
|
Changes in Mean Velocity (Hyperventilation)
Time Frame: 30 minutes
|
By performing Hyperventilation, changes in Mean Velocity, measure in m/s from baseline to 30 minutes after caffeine ingestion.
|
30 minutes
|
Changes in Mean Velocity (Short-term memory test)
Time Frame: 30 minutes
|
With short-term memory test, changes in Mean Velocity, measure in m/s from baseline to 30 minutes after caffeine ingestion.
|
30 minutes
|
Changes in Mean Velocity (Vocabulary problem)
Time Frame: 30 minutes
|
With solving vocabulary problems, changes in Mean Velocity, measure in m/s from baseline to 30 minutes after caffeine ingestion.
|
30 minutes
|
Changes in Mean Velocity (Math problem.)
Time Frame: 30 minutes
|
With solving math problems, changes in Mean Velocity, measure in m/s from baseline to 30 minutes after caffeine ingestion.
|
30 minutes
|
Changes in Peak systolic velocity (Basal)
Time Frame: 30 minutes
|
Changes in Mean Velocity, measure in m/s from baseline to 30 minutes after caffeine ingestion.
|
30 minutes
|
Changes in Peak systolic velocity (Hypoventilation)
Time Frame: 30 minutes
|
By performing Hypoventilation, changes in Peak systolic velocity, measure in m/s from baseline to 30 minutes after caffeine ingestion.
|
30 minutes
|
Changes in Peak systolic velocity (Hyperventilation)
Time Frame: 30 minutes
|
By performing Hyperventilation, changes in Peak systolic velocity, measure in m/s from baseline to 30 minutes after caffeine ingestion.
|
30 minutes
|
Changes in Peak systolic velocity (Short-term memory test)
Time Frame: 30 minutes
|
With short-term memory test, changes in Peak systolic velocity, measure in m/s from baseline to 30 minutes after caffeine ingestion.
|
30 minutes
|
Changes in Peak systolic velocity (Vocabulary problems)
Time Frame: 30 minutes
|
With solving vocabulary problems, changes in Peak systolic velocity, measure in m/s from baseline to 30 minutes after caffeine ingestion.
|
30 minutes
|
Changes in Peak systolic velocity (Math problems)
Time Frame: 30 minutes
|
With solving math problems, changes in Peak systolic velocity, measure in m/s from baseline to 30 minutes after caffeine ingestion.
|
30 minutes
|
Changes in Vend-diastolic velocity (Basal)
Time Frame: 30 minutes
|
Changes in Mean Velocity, measure in m/s from baseline to 30 minutes after caffeine ingestion.
|
30 minutes
|
Changes in Vend-diastolic velocity (Hypoventilation)
Time Frame: 30 minutes
|
By performing Hypoventilation, changes in Vend-diastolic velocity, measure in m/s from baseline to 30 minutes after caffeine ingestion.
|
30 minutes
|
Changes in Vend-diastolic velocity (Hyperventilation)
Time Frame: 30 minutes
|
By performing Hyperventilation, changes in Vend-diastolic velocity, measure in m/s from baseline to 30 minutes after caffeine ingestion.
|
30 minutes
|
Changes in Vend-diastolic velocity (Short-term memory test)
Time Frame: 30 minutes
|
With short-term memory test, changes in Vend-diastolic velocity, measure in m/s from baseline to 30 minutes after caffeine ingestion.
|
30 minutes
|
Changes in Vend-diastolic velocity (Vocabulary problems)
Time Frame: 30 minutes
|
With solving vocabulary problems, changes in Vend-diastolic velocity, measure in m/s from baseline to 30 minutes after caffeine ingestion.
|
30 minutes
|
Changes in Vend-diastolic velocity (Math problems)
Time Frame: 30 minutes
|
With solving math problems, changes in Vend-diastolic velocity, measure in m/s from baseline to 30 minutes after caffeine ingestion.
|
30 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in Heart Rate (Basal)
Time Frame: 30 minutes
|
Changes in Heart Rate, measure in bpm from baseline to 30 minutes after caffeine ingestion.
|
30 minutes
|
Changes in Heart Rate (Hypoventilation)
Time Frame: 30 minutes
|
By performing Hypoventilation, changes in Heart Rate, measure in bpm from baseline to 30 minutes after caffeine ingestion.
|
30 minutes
|
Changes in Heart Rate (Hyperventilation)
Time Frame: 30 minutes
|
By performing Hyperventilation, changes in Heart Rate, measure in bpm from baseline to 30 minutes after caffeine ingestion.
|
30 minutes
|
Changes in Heart Rate (Short-term memory test)
Time Frame: 30 minutes
|
With short-term memory test, changes in Heart Rate, measure in bpm from baseline to 30 minutes after caffeine ingestion.
|
30 minutes
|
Changes in Heart Rate (Vocabulary problems)
Time Frame: 30 minutes
|
With solving vocabulary problems, changes in Heart Rate, measure in bpm from baseline to 30 minutes after caffeine ingestion.
|
30 minutes
|
Changes in Heart Rate (Math problems)
Time Frame: 30 minutes
|
With solving math problems, changes in Heart Rate, measure in bpm from baseline to 30 minutes after caffeine ingestion.
|
30 minutes
|
Collaborators and Investigators
Investigators
- Principal Investigator: Hélder Santos, PhD, Polytechnic Institute of Coimbra - Coimbra Health School
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CCBF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular System
-
Amit N. Patel MD MSUnknownCardiovascular System Diseases (& [Cardiac])United States
-
University of Mississippi, OxfordActive, not recruiting
-
Hospices Civils de LyonCompleted
-
Mayo ClinicCompletedCardiovascular System | HemodynamicsUnited States
-
Case Western Reserve UniversityAmerican Heart AssociationCompletedCardiovascular Disease | HIVUnited States
-
St Vincent's Hospital, SydneyMerck Sharp & Dohme LLCCompleted
-
Nutrasource Pharmaceutical and Nutraceutical Services...University of Guelph; Biodroga Inc.CompletedCardiovascular DiseaseCanada
-
Humanitas Clinical and Research CenterCompletedAnesthesia, General | Cardiovascular System | NeurosurgeryItaly
-
Fudan UniversityActive, not recruitingCardiovascular System | Respiratory SystemChina
-
Tao XinRecruitingCardiovascular Diseases | Nervous System DiseasesChina
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States